Navigation Links
Byetta Pancreatic Cancer Allegation Lawsuits Offered through Resource4thePeople
Date:4/17/2013

San Diego, CA (PRWEB) April 17, 2013

http://www.resource4thepeople.com/defectivedrugs/byetta.html

Resource4thePeople announced today that its attorneys are offering free legal consultations to patients who used a certain type of diabetes drug including Byetta and allegedly suffered severe side effects of the pancreas.

The consultations are being offered in response to a large volume of inquiries from consumers over the Food and Drug Administration’s announcement* that it is investigating reports of possible increased risk of pancreatitis and pre-cancerous findings of the pancreas from incretin mimetic drugs such as Byetta for type 2 diabetes.

An FDA spokesman said that the findings were based on examination of a small number of pancreatic tissue specimens taken from patients after they died from unspecified causes.

The FDA has asked the researchers to provide the methodology used to collect and study these specimens and to provide the tissue samples so the agency can further investigate potential pancreatic toxicity associated with the incretin mimetics.

The FDA identified these drugs as exenatide (Byetta, Bydureon), liraglutide (Victoza), sitagliptin (Januvia, Janumet, Janumet XR, Juvisync), saxagliptin (Onglyza, Kombiglyze XR), alogliptin (Nesina, Kazano, Oseni), and linagliptin (Tradjenta, Jentadueto).

“There are a significant number of Americans who treat their diabetes with these medications and the FDA announcement generated a large number of inquiries from patients who have asked about their legal options in cases in which they allegedly suffered these serious side effects,” said Resource4thePeople.

“As a result, out national legal network is now offering free legal consultations in which consumers may determine their eligibility to file a claim or lawsuit and seek compensation for the medical expenses, pain and suffering and other costs that may have been incurred.”

Resource4thePeople notes that there may be legal time limits involved in such actions and is requesting consumers to make contact as soon as possible in order to preserve all legal options available.

Byetta was originally approved by the FDA and released onto the market in 2005, with its primary function being to help patients with diabetes manage their condition.

It is applied by injection and it and the other incretin mimetics, according to the FDA, mimic the incretin hormones that the body usually produces naturally to stimulate the release of insulin in response to a meal.

The agency said the medications are used along with diet and exercise to lower blood sugar in adults with type 2 diabetes.

In its announcement,* the FDA reiterated a previous public warning “about postmarketing reports of acute pancreatitis, including fatal and serious nonfatal cases, associated with the use of incretin mimetic drugs exenatide and sitagliptin.”

An agency officials also said that a recently published study that examined insurance records also found the use of exenatide or sitagliptin could double the risk of developing acute pancreatitis.

The official said that the Warnings and Precautions section of the drug labels and the patient Medication Guides for incretin mimetics contain warnings about the risk of acute pancreatitis.

Resource4thePeople also is providing consumers some of the cautionary analysis about Byetta and its sister drugs. Here are some of the warnings and precautions taken from the agency’s web site:**

What is the most important information I should know about BYETTA?

Serious side effects can happen in people who take BYETTA, including inflammation of the pancreas (pancreatitis) which may be severe and lead to death.

Before taking BYETTA, tell your healthcare provider if you have had:

  •     pancreatitis.
  •     stones in your gallbladder (gallstones).
  •     a history of alcoholism.
  •     high blood triglyceride levels.

These medical conditions can make you more likely to get pancreatitis in general. It is not known if having these conditions will lead to a higher chance of getting pancreatitis while taking BYETTA.

                                    While taking BYETTA:

Call your healthcare provider right away if you have pain in your stomach area (abdomen) that is severe, and will not go away. The pain may happen with or without vomiting. The pain may be felt going from your abdomen through to your back. These may be symptoms of pancreatitis.

Resource4thePeople also is recommending that consumers update themselves on media reports about the side effects, such as one recently posted by Bloomberg News about the research study and concerns about the safety of the medication as voiced by the FDA earlier and by physicians:***

“Doctors have been concerned that this category of diabetes treatments may damage the pancreas since the FDA said in 2007 it received a high number of reports of pancreatitis in patients taking Byetta.

“The agency issued a similar alert for Januvia in 2009. An analysis of insurance records published last month in the journal JAMA Internal Medicine showed such drugs may double a user’s risk of pancreatitis. That hasn’t stopped these medicines from becoming multibillion-dollar drugs.”

http://www.resource4thepeople.com/defectivedrugs/byetta.html

Sources:
*http://www.fda.gov/Drugs/DrugSafety/DrugSafetyPodcasts/ucm344232.htm
**http://www.fda.gov/downloads/Drugs/DrugSafety/UCM191084.pdf
***http://www.bloomberg.com/news/2013-03-22/diabetes-drugs-may-cause-damage-to-pancreas-study-finds.html

Read the full story at http://www.prweb.com/releases/2013/4/prweb10635340.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. d'Oliveira & Associates Releases New Byetta Infographic on Potential Kidney and Pancreas Health Risks Associated with the Drug
2. Blood Test Might Spot Pancreatic Cancer Early, Study Finds
3. New metabolite-based diagnostic test could help detect pancreatic cancer early
4. Dana-Farber Scientists find potential loophole in pancreatic cancer defenses
5. Research suggests popular diabetes drugs can cause abnormal pancreatic growth in humans
6. IU researchers receive $3.2 million to develop, improve therapies for pancreatic cancer
7. Bitter melon juice prevents pancreatic cancer in mouse models
8. Cleveland Clinic study shows bariatric surgery restores pancreatic function by targeting belly fat
9. Molecular master switch for pancreatic cancer identified, potential predictor of treatment outcome
10. Clinical trial looks to improve pancreatic cancer survival rates
11. Blood Test Might Help Guide Pancreatic Cancer Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... 2017 , ... Accreditation Commission for Health Care (ACHC) is ... (HCAOA). This agreement allows HCAOA members to receive special pricing on ACHC’s Home ... University (AU) educational resources that help prepare HCAOA members for ACHC Accreditation. , ...
(Date:4/28/2017)... Clara, CA (PRWEB) , ... April 28, 2017 ... ... is pleased to announce the integration of Microsoft(R) Word(TM) Online(TM), which enables sleep ... user experience, since it streamlines the reporting process and provides a familiar interface ...
(Date:4/28/2017)... ... ... Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ) announced today that ... as “stable.” At the same time, the ratings agency cautioned that the company’s rating ... “capital adequacy” thresholds required for its strong rating. , “Horizon is committed to being ...
(Date:4/28/2017)... ... April 28, 2017 , ... GlycoMark, ... the GlycoMark test throughout the Northeast U.S. , GlycoMark is the only ... The GlycoMark test provides a clinically proven one- to two-week measure of hyperglycemic ...
(Date:4/28/2017)... ... 2017 , ... Ushio America proudly introduces the new ... solution for F32T8 fluorescent lamps on most instant-start and programmed-start electronic ballasts so ... lamps utilize the existing electronic ballast, saving labor and maintenance costs. It’s easy ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... --  ZappRx, Inc ., a digital health company focused on ... it closed $25 million in Series B funding led by ... Seattle that is part of a ... B round included participation from SR One , who ... (formerly Google Ventures). As part of the financing, ...
(Date:4/20/2017)... , April 20, 2017 Eyevensys, ... the first non-viral gene expression technology that enables the ... eye to address a wide range of ophthalmic diseases, ... and Healthcare products Regulatory Agency (MHRA) to advance its ... ...
(Date:4/19/2017)... - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the "Company"), announces that ... Conference 2017 at the Sheraton Hotel in Toronto, Ontario ... of the Company is scheduled to present on Tuesday, May 2 ... the Chairman of the Board, Tony Holler will also ... For more ...
Breaking Medicine Technology: